GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Beneish M-Score

Xeris Biopharma Holdings (Xeris Biopharma Holdings) Beneish M-Score : -2.40 (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.4 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Xeris Biopharma Holdings's Beneish M-Score or its related term are showing as below:

XERS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.74   Med: 0.11   Max: 139.23
Current: -2.4

During the past 8 years, the highest Beneish M-Score of Xeris Biopharma Holdings was 139.23. The lowest was -2.74. And the median was 0.11.


Xeris Biopharma Holdings Beneish M-Score Historical Data

The historical data trend for Xeris Biopharma Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Beneish M-Score Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial 60.76 1.89 139.23 -1.68 -2.40

Xeris Biopharma Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.68 -2.08 -2.26 -1.87 -2.40

Competitive Comparison of Xeris Biopharma Holdings's Beneish M-Score

For the Biotechnology subindustry, Xeris Biopharma Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xeris Biopharma Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Beneish M-Score falls into.



Xeris Biopharma Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Xeris Biopharma Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8551+0.528 * 0.963+0.404 * 0.9884+0.892 * 1.4868+0.115 * 1.8377
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7134+4.679 * -0.054544-0.327 * 1.2688
=-2.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $39.2 Mil.
Revenue was 44.39 + 48.32 + 38.008 + 33.196 = $163.9 Mil.
Gross Profit was 36.82 + 40.119 + 30.453 + 27.877 = $135.3 Mil.
Total Current Assets was $156.3 Mil.
Total Assets was $322.6 Mil.
Property, Plant and Equipment(Net PPE) was $29.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $13.2 Mil.
Selling, General, & Admin. Expense(SGA) was $146.1 Mil.
Total Current Liabilities was $95.2 Mil.
Long-Term Debt & Capital Lease Obligation was $225.7 Mil.
Net Income was -13.39 + -12.189 + -19.842 + -16.834 = $-62.3 Mil.
Non Operating Income was 2.126 + -1.888 + 0.767 + 1.359 = $2.4 Mil.
Cash Flow from Operations was 7.471 + -14.61 + -13.744 + -26.14 = $-47.0 Mil.
Total Receivables was $30.8 Mil.
Revenue was 33.144 + 29.725 + 25.306 + 22.073 = $110.2 Mil.
Gross Profit was 26.853 + 24.465 + 20.496 + 15.8 = $87.6 Mil.
Total Current Assets was $186.8 Mil.
Total Assets was $344.5 Mil.
Property, Plant and Equipment(Net PPE) was $9.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.7 Mil.
Selling, General, & Admin. Expense(SGA) was $137.7 Mil.
Total Current Liabilities was $73.6 Mil.
Long-Term Debt & Capital Lease Obligation was $196.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(39.197 / 163.914) / (30.83 / 110.248)
=0.239131 / 0.279642
=0.8551

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(87.614 / 110.248) / (135.269 / 163.914)
=0.794699 / 0.825244
=0.963

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (156.264 + 29.175) / 322.602) / (1 - (186.818 + 9.508) / 344.522)
=0.425177 / 0.43015
=0.9884

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=163.914 / 110.248
=1.4868

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.668 / (12.668 + 9.508)) / (13.16 / (13.16 + 29.175))
=0.571248 / 0.310854
=1.8377

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(146.095 / 163.914) / (137.745 / 110.248)
=0.891291 / 1.24941
=0.7134

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((225.696 + 95.193) / 322.602) / ((196.477 + 73.621) / 344.522)
=0.99469 / 0.783979
=1.2688

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-62.255 - 2.364 - -47.023) / 322.602
=-0.054544

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Xeris Biopharma Holdings has a M-score of -2.40 suggests that the company is unlikely to be a manipulator.


Xeris Biopharma Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description

Traded in Other Exchanges
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Executives
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper officer: Chief Financial Officer XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff director C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr officer: See Remarks DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Paul R Edick director, officer: See Remarks C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley director XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski officer: Chief Scientific Officer C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Beth Hecht officer: See Remarks C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Kenneth Erland Johnson officer: See Remarks C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Barbara-jean Anne Bormann-kennedy director 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Marla Persky director ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Barry M. Deutsch officer: See Remarks OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015

Xeris Biopharma Holdings (Xeris Biopharma Holdings) Headlines

From GuruFocus